James Shun Dah Hu MD FACP
Genitourinary Oncology, Hematologic Oncology, Sarcoma
e.g.: Family medicine at Valley Associates
Join to view full profile
127 S San Vicente BlvdLos Angeles, CA 90048
Phone+1 310-423-8530
Fax+1 310-423-4759
Dr. Hu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Hu is an oncologist based in Los Angeles, CA, specializing in genitourinary oncology, hematologic oncology, and sarcoma. He completed his medical degree at Uniformed Services University and residency at William Beaumont Army Medical Center, followed by a fellowship in hematology and medical oncology at Madigan Army Medical Center. Additionally, he holds MAs in Strategic Studies and Military History. Dr. Hu has research experience in areas including chondrosarcoma and malignant fibrous histiocytoma and has contributed to several publications, notably on topics like physician leadership, burnout, and cancer treatment therapies. He has participated in clinical trials involving various cancer treatments and received recognition as a Regional Top Doctor by Castle Connolly in 2014.
Education & Training
University of Southern CaliforniaEdD, Organizational Change and Leadership, 2019 - 2021
United States Army War CollegeMA, Strategic Studies, 2009 - 2011- Norwich UniversityMA, Military History, 2007 - 2009
Madigan Army Medical CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
William Beaumont Army Medical CenterResidency, Internal Medicine, 1987 - 1990
Certifications & Licensure
CA State Medical License 2000 - 2027
PA State Medical License 1989 - 2000
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2015-2017
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
- Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Publications & Presentations
PubMed
- Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.Alice P Chen, Christina L Rosenberger, Nancy Moore, Jared C Foster, Abdul Rafeh Naqash
Journal of Clinical Oncology. 2026-06-01 - 6 citationsPhysician Leadership and Burnout: The Need for Agency; a Qualitative Study of an Academic Institution.James S Hu, Louis N Pangaro, Bami M Gloria Andrada, Rachel C Ceasar, Jennifer L Phillips
Journal of Healthcare Leadership. 2024-01-01 - 94 citationsAtezolizumab for Advanced Alveolar Soft Part Sarcoma.Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, Nancy Moore, Jared C Foster
The New England Journal of Medicine. 2023-09-07
Press Mentions
Cedars-Sinai Cancer Expands Sarcoma ProgramNovember 3rd, 2025
Cancer Survival Takes a Hit with Alternative MedicineAugust 11th, 2017- Already Too Late to Stop Costly Radiotherapy and Surgery Technologies?August 25th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: